Evidence Grade E — Very limited evidence. 6 published studies. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
Vesugen is a synthetic tripeptide from the Khavinson bioregulator programme, proposed to target blood vessel lining (vascular endothelium). Among Khavinson vascular peptides, it has the strongest mechanistic data, with quantitative cell proliferation measurements and specific DNA binding studies. No human clinical trials have been conducted and it has no regulatory approval.
Vesugen is also known by these brand and alternate names:
6 published studies: 3 human, 3 animal, 1 in-vitro, 0 reviews
Vesugen has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. In vitro studies in vascular tissue cultures reported increased Ki-67 expression (a cell proliferation marker), with greater effects observed in senescent versus young tissue cultures.
As with other Khavinson bioregulator peptides, the proposed vascular-targeting mechanisms and gene-regulatory effects have not been independently validated or tested in clinical trials. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Vesugen binds to specific DNA sequences in gene promoter regions, with a validated gene target (Ki-67/MKI67) involved in cell proliferation. Molecular docking studies and vascular tissue culture experiments have been published. These mechanisms are based on in vitro and computational work from the originating research group.
Research suggests approximately 8-12 indexed studies exist, with quantitative data on cell proliferation markers and DNA binding that provide stronger mechanistic grounding than most Khavinson peptides. Effects were more pronounced in aged versus young tissue cultures — an observation consistent with the bioregulation theory. However, virtually all research originates from a single laboratory. No large controlled human trials, no pharmacokinetic data, and no independent Western replication exist. Products from unregulated channels lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for Vesugen sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
Vesugen is a synthetic tripeptide bioregulator with the sequence Lys-Glu-Asp (KED). Its molecular weight is 390.39 Da with the molecular formula C15H26N4O8 (PubChem CID 87571363, ChEBI 159909). Developed by Vladimir Khavinson as part of the cytomedine program, Vesugen targets vascular endothelium. Also known as T-38. Vesugen contains the complete Vilon sequence (Lys-Glu) plus aspartic acid. It is the most mechanistically characterized of the Khavinson vascular peptides, with approximately 8-12 PubMed-indexed studies.
Research suggests Vesugen binds to the minor groove of double-stranded DNA, forming donor-acceptor bonds and hydrogen bonds with specific nucleotide sequences (CATC, CACC, GGCG, TGGC in promoter regions). The primary validated gene target is MKI67 (Ki-67 proliferation marker), with molecular docking demonstrating binding to the MKI67 promoter at the CATC sequence (interaction energy -7.04 to -8.14 kcal/mol). Research suggests Vesugen upregulates Ki-67, normalizes endothelin-1, restores connexins (Cx37, Cx40, Cx43), upregulates SIRT1, and reduces p53, p16, p21 (senescence markers) and MMP-9 in aging fibroblasts.
Ki-67 and MKI67 promoter binding studies (Khavinson et al. 2014/2015) in vascular tissue explant cultures showed Ki-67 expression area increased 1.25-fold (25%) in young cultures and 1.97-fold (97%) in senescent cultures at 20 ng/mL. Neurogenesis studies (Khavinson et al. 2021) showed 20-27% increase in functional mushroom spines in hippocampal neurons under synaptotoxic conditions. Skin fibroblast studies (Linkova et al. 2016) showed MMP-9 inhibition and Ki-67 enhancement during replicative aging.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 6 vendor listings
View pricing data across vendors and countries for Vesugen
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation. In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval. Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Palopegteriparatide is marketed as Yorvipath (Ascendis Pharma, approved August 2024). It is the first FDA-approved PTH replacement therapy for hypoparathyroidism, a condition that previously had no approved hormone replacement and was managed only with high doses of calcium supplements and active vitamin D — an approach that does not fully normalise calcium metabolism. In the PaTHway trial, 79% of patients achieved independence from calcium and active vitamin D supplements while maintaining normal blood calcium levels, compared to 5% on placebo. This represents a fundamental shift in managing hypoparathyroidism — from supplementation to actual hormone replacement. Patients also showed improvements in kidney function markers and bone metabolism parameters.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
